Prakt. lékáren. 2014; 10(1): 26-29

Pharmaceutical care in patients with inflammatory bowel disease

Petr Červený
Ústavní lékárna FN Plzeň Bory

Inflammatory bowel diseases are chronic inflammatory processes, primarily affecting the intestinal mucosa. The chronic course of the disease

is characterized by periods of remission alternating with acute flare-ups of the disease. Inflammatory bowel diseases are conditions with an

increasing severity given their growing incidence, chronic nature, difficult therapeutic management, and predominance in the highly productive

age. Preparations of 5-aminosalicylic acid (5-ASA), corticosteroids, immunosuppressants, and antibiotics remain the mainstay of conservative



treatment: The goal of the treatment is remission induction, its maintenance, and improvement in the quality of life of the patient. The paper aims

to summarize the existing therapeutic options and discuss administration of pharmaceutical care in patients with inflammatory bowel disease.

Keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, mesalazine, pharmaceutical care

Published: February 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Červený P. Pharmaceutical care in patients with inflammatory bowel disease. Praktické lékárenství. 2014;10(1):26-29.
Download citation

References

  1. Ehrmann J, Konečný M. Diagnostika a léčba idiopatických střevních zánětů. Med. praxi 2011; 8(10): 435-437.
  2. Lukáš K. Několik poznámek k léčbě idiopatických střevních zánětů. Interní Med. 2012; 14(12): 466-469.
  3. Lukáš M. Možnosti medikamentózní léčby u Crohnovy nemoci a ulcerózní kolitidy. Interní Med. 2011; 13(11): 422-426.
  4. Marek J, a kol. Farmakoterapie vnitřních nemocí. 4., zcela přepracované a doplněné vydání, Grada 2010.
  5. Mikro-verze AISLP ČR, 3.2013.
  6. Lukáš M. Biologická léčba Crohnovy nemoci. Med. praxi 2012; 9(2): 53-56.
  7. Bortlík M, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 2. a přepracované vydání. Gastroent Hepatol 2012; 66(1): 12-22.
  8. Zbořil V. Mikroflóra trávicího traktu, Grada 2005.
  9. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013; 29(2): 184-189. Go to original source... Go to PubMed...
  10. Kohout P, et al. Výživa u pacientů s idiopatickými střevními záněty. Praha: Maxdorf, 2004.
  11. Cerveny P, et al. Nonadherence in inflammatory bowel disease: Results of factor analysis. Inflamm Bowel Dis 2007; 13: 1244-1249. Go to original source... Go to PubMed...
  12. Cerveny P, et al. Non-adherence in inflammatory bowel disease in Czech Republic, J Crohn's Colitis 2007; 1: 77-81. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.